UY33985A - Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida - Google Patents

Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida

Info

Publication number
UY33985A
UY33985A UY0001033985A UY33985A UY33985A UY 33985 A UY33985 A UY 33985A UY 0001033985 A UY0001033985 A UY 0001033985A UY 33985 A UY33985 A UY 33985A UY 33985 A UY33985 A UY 33985A
Authority
UY
Uruguay
Prior art keywords
dihydroimidazo
salts
substituted quinazoline
quinazoline
substituted
Prior art date
Application number
UY0001033985A
Other languages
English (en)
Inventor
Dr Jan-Georg Peters
Dr Hans-Christian Militzer
Dr Hartwig Mueller
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43984137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33985(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY33985A publication Critical patent/UY33985A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sal de diclorhidrato de 2-amino-N-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo-[1,2-c]quinazolin- 5-il]pirimidin-5-carboxamida de Fórmula (II), o un tautómero, solvato o hidrato de la misma.
UY0001033985A 2011-04-05 2012-03-28 Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida UY33985A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Publications (1)

Publication Number Publication Date
UY33985A true UY33985A (es) 2012-10-31

Family

ID=43984137

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033985A UY33985A (es) 2011-04-05 2012-03-28 Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida

Country Status (42)

Country Link
US (2) US10383876B2 (es)
EP (2) EP2508525A1 (es)
JP (2) JP5763834B2 (es)
KR (1) KR101937501B1 (es)
CN (1) CN103649091B (es)
AP (1) AP3709A (es)
AR (1) AR085718A1 (es)
AU (1) AU2012238891B2 (es)
BR (1) BR112013025549A2 (es)
CA (1) CA2832123C (es)
CL (1) CL2013002870A1 (es)
CO (1) CO6781534A2 (es)
CR (1) CR20130511A (es)
CU (1) CU24208B1 (es)
CY (1) CY1116231T1 (es)
DK (1) DK2694508T3 (es)
DO (1) DOP2013000223A (es)
EA (1) EA023646B1 (es)
EC (1) ECSP13013006A (es)
ES (1) ES2529653T3 (es)
GT (1) GT201300234A (es)
HR (1) HRP20150138T1 (es)
IL (1) IL228561A (es)
JO (1) JO2958B1 (es)
MA (1) MA35014B1 (es)
ME (1) ME02021B (es)
MX (1) MX336057B (es)
MY (1) MY169452A (es)
PE (1) PE20141038A1 (es)
PH (1) PH12013502065A1 (es)
PL (1) PL2694508T3 (es)
PT (1) PT2694508E (es)
RS (1) RS53811B1 (es)
SG (1) SG193595A1 (es)
SI (1) SI2694508T1 (es)
SM (1) SMT201500037B (es)
TN (1) TN2013000401A1 (es)
TW (2) TWI592158B (es)
UA (1) UA111604C2 (es)
UY (1) UY33985A (es)
WO (1) WO2012136553A1 (es)
ZA (1) ZA201307105B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EA031493B9 (ru) 2013-04-08 2019-12-18 Байер Фарма Акциенгезельшафт Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)
AU2014280174A1 (en) 2013-06-14 2015-12-03 Bayer Pharma Aktiengesellschaft Anti-TWEAKR antibodies and uses thereof
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN107683138A (zh) * 2015-03-09 2018-02-09 拜耳制药股份公司 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途
MX2017011635A (es) * 2015-03-09 2018-02-09 Bayer Pharma AG Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
CA2980390A1 (en) 2015-03-23 2016-09-29 Bayer Pharma Aktiengesellschaft Anti-ceacam6 antibodies and uses thereof
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
CN109072307A (zh) 2016-02-01 2018-12-21 拜耳制药股份公司 Copanlisib生物标志物
US20190038632A1 (en) 2016-02-01 2019-02-07 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
JOP20170053B1 (ar) 2016-03-02 2021-08-17 Eisai Randd Man Co Ltd مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
EP3426657B1 (en) * 2016-03-08 2022-07-13 Bayer Pharma Aktiengesellschaft 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CN109729716B (zh) 2016-09-23 2022-03-15 拜耳制药股份公司 Pi3k-抑制剂的组合产品
CA3045041A1 (en) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
US11684672B2 (en) 2017-02-24 2023-06-27 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-PD-1 antibody
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
JP2020533292A (ja) 2017-09-08 2020-11-19 バイエル・コンシューマー・ケア・アクチェンゲゼルシャフトＢａｙｅｒ Ｃｏｎｓｕｍｅｒ Ｃａｒｅ ＡＧ コパンリシブの製剤
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
EP3843743A1 (en) 2018-08-28 2021-07-07 Bayer AS Combination of pi3k-inhibitors and targeted thorium conjugates
US20210369724A1 (en) * 2018-10-16 2021-12-02 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CA3113770A1 (en) * 2018-10-17 2020-04-23 Sandoz Ag Co-crystals comprising levothyroxine and a dicarboxylic acid
JP7195027B2 (ja) * 2018-12-27 2022-12-23 ホロスメディック 新規の化合物およびこれを含む抗癌活性増進用薬学組成物
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts
WO2025053315A1 (ko) * 2023-09-08 2025-03-13 파로스젠 주식회사 항암제 프로드러그 컨쥬게이트의 제조에서 팔라듐의 회수 및 제거 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588505A5 (es) 1972-06-08 1977-06-15 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
ES2312843T3 (es) 2002-09-30 2009-03-01 Bayer Healthcare Ag Derivados de azolpirimidina condensados.
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2244721A4 (en) 2008-01-14 2017-01-18 Bayer Intellectual Property GmbH Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
CA2796253A1 (en) 2010-04-16 2011-10-20 Bayer Intellectual Property Gmbh Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EA031493B9 (ru) 2013-04-08 2019-12-18 Байер Фарма Акциенгезельшафт Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)
CN105934256B (zh) 2013-12-03 2019-12-27 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
MX2017011635A (es) 2015-03-09 2018-02-09 Bayer Pharma AG Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
CN107683138A (zh) * 2015-03-09 2018-02-09 拜耳制药股份公司 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途

Also Published As

Publication number Publication date
AU2012238891B2 (en) 2016-12-01
PL2694508T3 (pl) 2015-04-30
KR101937501B1 (ko) 2019-01-10
CN103649091B (zh) 2016-06-22
IL228561A (en) 2015-10-29
PT2694508E (pt) 2015-02-10
US9636344B2 (en) 2017-05-02
ES2529653T3 (es) 2015-02-24
EP2508525A1 (en) 2012-10-10
HRP20150138T1 (hr) 2015-05-08
JP5826961B2 (ja) 2015-12-02
HK1195907A1 (zh) 2014-11-28
EP2694508A1 (en) 2014-02-12
NZ616198A (en) 2015-09-25
CA2832123A1 (en) 2012-10-11
PH12013502065A1 (en) 2016-06-29
TWI592158B (zh) 2017-07-21
SG193595A1 (en) 2013-10-30
MX2013011583A (es) 2013-12-16
TW201249847A (en) 2012-12-16
TN2013000401A1 (en) 2015-03-30
US20160193219A1 (en) 2016-07-07
EA201391470A1 (ru) 2014-03-31
CL2013002870A1 (es) 2014-06-20
AP2013007219A0 (en) 2013-10-31
AU2012238891A1 (en) 2013-10-24
BR112013025549A2 (pt) 2016-12-27
IL228561A0 (en) 2013-12-31
CU20130133A7 (es) 2014-01-29
AR085718A1 (es) 2013-10-23
CN103649091A (zh) 2014-03-19
JP2014510119A (ja) 2014-04-24
SI2694508T1 (sl) 2015-03-31
MA35014B1 (fr) 2014-04-03
UA111604C2 (uk) 2016-05-25
ECSP13013006A (es) 2013-12-31
MX336057B (es) 2016-01-07
US10383876B2 (en) 2019-08-20
JP5763834B2 (ja) 2015-08-12
DOP2013000223A (es) 2013-11-15
GT201300234A (es) 2015-01-16
RS53811B1 (sr) 2015-06-30
US20140072529A1 (en) 2014-03-13
DK2694508T3 (en) 2015-02-16
TW201637656A (zh) 2016-11-01
KR20140021637A (ko) 2014-02-20
CU24208B1 (es) 2016-11-29
EP2694508B1 (en) 2014-11-19
CR20130511A (es) 2013-12-04
CA2832123C (en) 2018-09-11
PE20141038A1 (es) 2014-09-05
TWI549954B (zh) 2016-09-21
CY1116231T1 (el) 2017-02-08
CO6781534A2 (es) 2013-10-31
JO2958B1 (en) 2016-03-15
ZA201307105B (en) 2014-11-26
MY169452A (en) 2019-04-11
SMT201500037B (it) 2015-05-05
EA023646B1 (ru) 2016-06-30
AP3709A (en) 2016-05-31
WO2012136553A1 (en) 2012-10-11
JP2015164936A (ja) 2015-09-17
ME02021B (me) 2015-05-20

Similar Documents

Publication Publication Date Title
UY33985A (es) Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34004A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
CY1119804T1 (el) Συντηγμενες τετρα- ή πεντα-κυκλικες διϋδροδιαζεπινοκαρβαζολονες ως αναστολεις parp
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34039A (es) Compuestos fungicidas
UY34034A (es) Triazolopiridinas
UY33970A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
UY4149Q (es) Golosina para mascota
UY34374A (es) Benzilindazoles sustituidos
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201491304A1 (ru) Конденсированные тетра- или пентациклические пиридофталазиноны в качестве ингибиторов parp
UY33978A (es) Piridinonas bicíclicas nuevas.
UY34318A (es) ?derivados de isotiazolina útiles como compuestos insecticidas?
UY34559A (es) Inhibidores de bromodominios
UY34138A (es) Antagonistas de trpv4
UY34550A (es) Bencilpirazoles sustituidos
UY34502A (es) Arilos y heteroarilos bicíclicos inhibidores de los canales de sodio
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34301A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019